[go: up one dir, main page]

SG47447A1 - Compositions and methods for the prevention and diagnosis of lyme disease - Google Patents

Compositions and methods for the prevention and diagnosis of lyme disease

Info

Publication number
SG47447A1
SG47447A1 SG1996001704A SG1996001704A SG47447A1 SG 47447 A1 SG47447 A1 SG 47447A1 SG 1996001704 A SG1996001704 A SG 1996001704A SG 1996001704 A SG1996001704 A SG 1996001704A SG 47447 A1 SG47447 A1 SG 47447A1
Authority
SG
Singapore
Prior art keywords
diagnosis
prevention
compositions
methods
lyme disease
Prior art date
Application number
SG1996001704A
Other languages
English (en)
Inventor
Richard A Flavell
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of SG47447A1 publication Critical patent/SG47447A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG1996001704A 1990-06-15 1991-06-13 Compositions and methods for the prevention and diagnosis of lyme disease SG47447A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53896990A 1990-06-15 1990-06-15
US60255190A 1990-10-26 1990-10-26
US68235591A 1991-04-08 1991-04-08

Publications (1)

Publication Number Publication Date
SG47447A1 true SG47447A1 (en) 1998-04-17

Family

ID=27415285

Family Applications (2)

Application Number Title Priority Date Filing Date
SG1996001704A SG47447A1 (en) 1990-06-15 1991-06-13 Compositions and methods for the prevention and diagnosis of lyme disease
SG200004033A SG122738A1 (en) 1990-06-15 1991-06-13 Compositions and methods for the prevention and diagnosis of lyme disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG200004033A SG122738A1 (en) 1990-06-15 1991-06-13 Compositions and methods for the prevention and diagnosis of lyme disease

Country Status (6)

Country Link
US (3) US5747294A (fr)
EP (1) EP0536335A4 (fr)
JP (1) JPH06501382A (fr)
CA (1) CA2084413A1 (fr)
SG (2) SG47447A1 (fr)
WO (1) WO1992000055A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
DE69132417T2 (de) * 1990-07-06 2001-05-23 American Home Products Corp., Madison Impfstoff gegen die Lyme-Krankheit
CA2057536C (fr) * 1990-12-21 1999-10-26 John J. Dunn Clonage et expression des lipoproteines de borrelia
DK0598816T3 (da) * 1991-08-15 1999-11-22 Deutsches Krebsforsch Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner
US6676942B1 (en) * 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
ES2194010T3 (es) * 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
EP0671926B1 (fr) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Peptides immunomodulateurs
CA2105629A1 (fr) * 1992-09-14 1994-03-15 Robert S. Becker Potentialisation de la reaction immunogenique
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
EP0757556B1 (fr) * 1994-04-11 2006-06-14 Wyeth Holdings Corporation Bacterine de borrelia burgdorferi
US6312907B1 (en) 1995-04-24 2001-11-06 The Texas A & M University System DbpA compositions and methods of use
US6248517B1 (en) 1995-04-24 2001-06-19 The Texas A & M University System Decorin binding protein compositions and methods of use
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
US6214355B1 (en) 1995-04-24 2001-04-10 Texas A & M University System DbpA compositions
US5932220A (en) * 1995-05-08 1999-08-03 Board Of Regents University Of Texas System Diagnostic tests for a new spirochete, Borrelia lonestari sp. nov.
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
CA2704354A1 (fr) * 1995-06-07 1996-12-19 Connaught Laboratories, Inc. Expression de lipoproteines
JP2002511760A (ja) 1997-06-30 2002-04-16 ジ・アドミニストレイターズ・オブ・ザ・トウレーン・エデユケーシヨナル・フアンド ライム病の診断および予防用組成物に有用な表面抗原およびタンパク質
WO2000006745A1 (fr) 1998-07-31 2000-02-10 Gundersen Lutheran Medical Foundation, Inc. UTILISATIONS, EN TANT QUE VACCIN, D'EPITOPE(S) BORRELIACIDAL DE PROTEINE C DE SURFACE EXTERIEURE (OSPC) DE $i(BORRELIA BURGDORFERI)
US6610306B2 (en) * 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
EP1865062A3 (fr) * 2000-08-18 2008-01-09 Research Foundation Of State University Of New York OspA modifiée de Borrelia burgdorferi
EP1311540B1 (fr) * 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Ospa du borrelia burgdorferi modifie
WO2006014292A2 (fr) * 2004-07-02 2006-02-09 Dattwyler Raymond J Vaccin oral permettant de lutter contre des infections a borrelia
WO2008057396A2 (fr) 2006-11-03 2008-05-15 Schering-Plough Ltd. Vaccin contre la maladie de lyme canine
US7546018B2 (en) 2007-01-13 2009-06-09 Ofs Fitel, Llc Fiber optic cabling for multi-dwelling unit (MDU) and commercial building deployments
EP2155782A2 (fr) 2007-03-26 2010-02-24 Dako Denmark A/S Complexes peptidiques du cmh et leurs utilisations dans des maladies infectieuses
EP3023436A1 (fr) 2007-07-03 2016-05-25 Dako Denmark A/S Procédés améliorés pour produire, marquer et utiliser des multimères du cmh
EP2197908A2 (fr) 2007-09-27 2010-06-23 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2009135118A2 (fr) 2008-05-02 2009-11-05 Virginia Commonwealth University Vaccin contre la maladie de lyme
WO2010009735A2 (fr) 2008-07-23 2010-01-28 Dako Denmark A/S Analyse et réparation combinatoires
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
JP2013511530A (ja) * 2009-11-17 2013-04-04 アバクシス， インコーポレイテッド ライム病抗体の検出のためのペプチドおよび方法
CN103118701B (zh) 2010-05-14 2017-10-24 百深公司 Ospa嵌合体及其在疫苗中的用途
US20120142023A1 (en) * 2010-12-02 2012-06-07 Ascoli Carl A Proteins and method for detection of lyme disease
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
ES2699812T3 (es) 2012-02-01 2019-02-12 Biopeptides Corp Péptidos de diagnóstico para la enfermedad de Lyme
US9562079B2 (en) 2012-04-18 2017-02-07 Zoetis Services Llc Vaccines and methods to treat lyme disease in dogs
EP3077409B1 (fr) 2013-12-06 2020-04-01 Biopeptides Corporation Peptides destinés au diagnostic de la maladie de lyme
US20190284261A1 (en) * 2016-11-07 2019-09-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs for use against lyme disease
WO2020127222A2 (fr) 2018-12-17 2020-06-25 Immudex Aps Panneau comprenant des multimères de borrelia cmh

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4754065A (en) * 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4691009A (en) * 1984-12-26 1987-09-01 Repligen Corporation Hybrid proteins produced by an ultrahigh prokaryotic expression system
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4721617A (en) * 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US4963483A (en) * 1987-10-13 1990-10-16 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
US5227293A (en) * 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
CA2025178A1 (fr) * 1989-10-02 1991-04-03 William G. Weisburg Sondes d'acide nucleique pour la detection des spirochetes de la maladie de lyme
DK0506868T4 (da) * 1989-12-22 2004-04-26 Mikrogen Molekularbiol Entw Immunologisk aktive proteiner fra Borrelia burgdorferi, tilhørende testkits og vaccine
US5217872A (en) * 1990-02-27 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Method for detection of borrelia burgdorferi antigens
CA2057536C (fr) * 1990-12-21 1999-10-26 John J. Dunn Clonage et expression des lipoproteines de borrelia

Also Published As

Publication number Publication date
US6344552B1 (en) 2002-02-05
US5747294A (en) 1998-05-05
EP0536335A4 (en) 1993-07-14
EP0536335A1 (fr) 1993-04-14
US6197301B1 (en) 2001-03-06
SG122738A1 (en) 2006-06-29
CA2084413A1 (fr) 1991-12-16
JPH06501382A (ja) 1994-02-17
WO1992000055A1 (fr) 1992-01-09

Similar Documents

Publication Publication Date Title
SG47447A1 (en) Compositions and methods for the prevention and diagnosis of lyme disease
AU6905391A (en) Methods and compositions for the treatment of hodgkin's disease
EP0808324A4 (fr) Compositions destinees au traitement et au diagnostic de maladies cardio-vasculaires et techniques correspondantes
AU5355094A (en) Therapeutic and diagnostic imaging compositions and methods
GB9223560D0 (en) Surgical/diagnostic aid
EP0542914A4 (en) Improved diagnostic and therapeutic compositions
EP0546728A3 (en) Physiological tear compositions and methods for their preparation
HUP9902068A3 (en) Methods and compositions for the diagnosis and treatment of cancer
GB9008788D0 (en) Diagnostic equipment
GB8900678D0 (en) Compositions for the prevention and medical treatment of parodonthopathy
IL105216A0 (en) Method and kit for the diagnosis of alzheimer's disease
EP0557388A4 (en) Diagnosis and treatment of multiple sclerosis
GB9006671D0 (en) Diagnostic method and compositions
ZA914435B (en) Treatment of disease
HU9202431D0 (en) Medical preparatives of local application
AU4841296A (en) Diagnosis of and compositions and methods for the treatment of disease
HK1013428A (en) Compositions and methods for the prevention and diagnosis of lyme disease
HUP0000570A3 (en) Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
IL93139A0 (en) Pharmaceutical compositions comprising suramin and methods for the use thereof
EP0726961A4 (fr) Diagnostic de maladies mentales
GB9010190D0 (en) Composition for the treatment of protozoal disease and their use
HUP0000476A3 (en) Use of 17 betha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
HU9303488D0 (en) Controlled precipitation of particulate diagnostic imaging contrast agents
IL88936A0 (en) Compositions for the prevention and treatment of periodontal disease
GB9123755D0 (en) Method of disease diagnosis